From: Improved survival among colon cancer patients with increased differentially expressed pathways
 |  | Stage 1 | Stage 2 | Stage 3 | Stage 4 |  | ||||
---|---|---|---|---|---|---|---|---|---|---|
Pathway | # Features (Genes) | Mean 1 | STD | Mean | STD | Mean | STD | Mean | STD | P value 2 |
Cell Cycle Control of Chromosomal Replication | 15 | 31.0 | 9.4 | 30.5 | 8.8 | 30.1 | 7.4 | 27.0 | 8.6 | 0.11 |
Estrogen-mediated S-phase Entry | 13 | 27.1 | 7.7 | 26.2 | 6.8 | 26.2 | 5.8 | 23.3 | 6.9 | 0.06 |
Thyroid Hormone Metabolism II | 12 | 24.3 | 5.5 | 24.3 | 5.5 | 24.7 | 5.7 | 22.8 | 5.6 | 0.33 |
Hepatic Fibrosis/Hepatic Stellate Cell Activation | 39 | 78.4 | 14.0 | 78.5 | 13.1 | 80.7 | 14.1 | 73.1 | 14.3 | 0.17 |
Cell Cycle: G1/S Checkpoint Regulation | 19 | 38.8 | 10.4 | 38.2 | 9.7 | 38.6 | 8.3 | 34.6 | 9.7 | 0.13 |
Melatonin Degradation I | 16 | 32.1 | 6.7 | 32.7 | 6.7 | 32.6 | 6.8 | 30.7 | 7.1 | 0.45 |
Serotonin Degradation | 17 | 34.7 | 7.3 | 34.5 | 7.1 | 34.8 | 7.7 | 32.5 | 7.5 | 0.28 |
Superpathway of Melatonin Degradation | 16 | 32.1 | 6.7 | 32.7 | 6.7 | 32.6 | 6.8 | 30.7 | 7.1 | 0.45 |
Cyclins and Cell Cycle Regulation | 20 | 41.2 | 10.9 | 40.3 | 10.1 | 40.4 | 8.6 | 36.3 | 9.9 | 0.09 |
Cell Cycle: G2/M DNA Damage Checkpoint Regulation | 15 | 31.2 | 9.8 | 30.1 | 8.7 | 30.0 | 7.9 | 26.8 | 9.0 | 0.09 |
GADD45 Signaling | 9 | 18.9 | 5.6 | 18.3 | 5.2 | 17.8 | 4.4 | 16.4 | 5.2 | 0.11 |
Mismatch Repair in Eukaryotes | 8 | 16.9 | 4.8 | 16.2 | 4.6 | 15.9 | 4.1 | 14.4 | 5.1 | 0.06 |
Mitotic Roles of Polo-Like Kinase | 17 | 35.5 | 9.6 | 34.6 | 9.0 | 34.0 | 8.0 | 30.9 | 8.6 | 0.07 |
Agranulocyte Adhesion and Diapedesis | 34 | 70.6 | 11.4 | 68.3 | 9.8 | 70.5 | 11.2 | 65.6 | 13.3 | 0.13 |
Hereditary Breast Cancer Signaling | 24 | 50.1 | 13.9 | 48.7 | 13.3 | 48.2 | 12.2 | 43.9 | 13.4 | 0.10 |
Granulocyte Adhesion and Diapedesis | 32 | 66.3 | 10.6 | 64.8 | 9.5 | 66.8 | 10.6 | 61.3 | 12.6 | 0.10 |
Nicotine Degradation III | 13 | 25.8 | 5.9 | 26.8 | 5.9 | 26.3 | 5.9 | 24.9 | 6.2 | 0.59 |
Nicotine Degradation II | 14 | 27.8 | 6.2 | 28.8 | 6.4 | 28.2 | 6.4 | 26.9 | 6.6 | 0.59 |
p53 Signaling | 20 | 40.8 | 11.2 | 40.6 | 10.4 | 40.7 | 9.7 | 36.4 | 11.0 | 0.15 |
Axonal Guidance Signaling | 60 | 121.2 | 20.6 | 121.9 | 20.7 | 122.5 | 21.1 | 113.5 | 22.9 | 0.18 |
Aryl Hydrocarbon Receptor Signaling | 25 | 51.4 | 13.5 | 50.1 | 11.6 | 50.6 | 10.7 | 46.3 | 12.8 | 0.16 |
Role of BRCA1 in DNA Damage Response | 14 | 29.5 | 8.2 | 28.6 | 7.7 | 27.9 | 7.3 | 25.2 | 7.9 | 0.05 |
ATM Signaling | 13 | 27.1 | 7.5 | 26.6 | 7.1 | 25.6 | 6.3 | 23.8 | 7.0 | 0.10 |
Complement System | 10 | 20.7 | 3.3 | 19.7 | 3.4 | 20.3 | 3.4 | 19.3 | 3.6 | 0.12 |
Superpathway of Serine and Glycine Biosynthesis I | 4 | 8.1 | 2.3 | 8.0 | 2.3 | 8.2 | 2.0 | 7.5 | 2.6 | 0.34 |
Atherosclerosis Signaling | 20 | 40.4 | 6.9 | 39.9 | 6.1 | 41.7 | 6.7 | 38.4 | 8.1 | 0.32 |
Role of CHK Proteins in Cell Cycle Checkpoint Control | 12 | 25.0 | 6.8 | 24.5 | 6.4 | 24.0 | 5.4 | 21.4 | 6.4 | 0.05 |
RAN Signaling | 6 | 12.6 | 4.1 | 11.8 | 3.7 | 12.1 | 3.4 | 11.0 | 4.0 | 0.15 |
Purine Nucleotides De Novo Biosynthesis II | 5 | 10.2 | 3.3 | 10.0 | 3.1 | 10.2 | 3.0 | 9.2 | 3.2 | 0.26 |
Eicosanoid Signaling | 13 | 26.1 | 4.0 | 26.1 | 4.3 | 27.0 | 4.7 | 25.0 | 5.0 | 0.37 |
Wnt/ß-catenin Signaling | 26 | 52.7 | 10.6 | 52.3 | 9.5 | 53.2 | 10.0 | 48.9 | 10.9 | 0.19 |